Immatics (IMTX) Income from Non-Controlling Interests (2019 - 2021)
Immatics (IMTX) posted Income from Non-Controlling Interests of -$33.6 million for Q2 2021, down 10692.4% sequentially from -$311713.2 in Q2 2020, and down 10692.4% YoY from N/an in Q2 2020.
Immatics (IMTX) Income from Non-Controlling Interests (2019 - 2021) Analysis & Trends
Immatics has reported Income from Non-Controlling Interests for 3 years, with the latest figure at -$33.6 million in Q2 2021.
- Quarterly Income from Non-Controlling Interests fell 10692.4% year-over-year to -$33.6 million in Q2 2021, while the trailing twelve-month figure through Sep 2024 was -$33.6 million (changed N/A YoY) and the FY2020 annual result came in at -$635968.0, up 38.01% from the prior year.
- Income from Non-Controlling Interests slipped to -$33.6 million in Q2 2021 per IMTX's latest filing, from -$311713.2 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$249049.7 in Q4 2019 and troughed at -$33.6 million in Q2 2021.
- A 3-year average of -$5.8 million and a median of -$297007.3 in 2019 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2020 and 2021: Income from Non-Controlling Interests fell 19.58% in 2020, then slumped 10692.4% in 2021.
- Over 3 years, Income from Non-Controlling Interests stood at -$249049.7 in 2019, then declined by 25.16% to -$311713.2 in 2020, then plunged by 10692.4% to -$33.6 million in 2021.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$33.6 million, -$311713.2, and -$302479.3 for Q2 2021, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -33.64 Mn |
| Jun 30, 2020 | -311,713.22 |
| Mar 31, 2020 | -302,479.29 |
| Dec 31, 2019 | -249,049.73 |
| Sep 30, 2019 | -291,535.27 |
| Jun 30, 2019 | -260,684.27 |